- Molecular NameDocetaxel
- Synonymdocetaxel; Docetaxel anhydrous; Docetaxel, Trihydrate; TXL
- Weight807.89
- Drugbank_IDDB01248
- ACS_NO114977-28-5
- Show 3D model
- LogP (experiment)4.258
- LogP (predicted, AB/LogP v2.0)3.14
- pkaN/A
- LogD (pH=7, predicted)3.13
- Solubility (experiment)0.000025 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-6.82
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors5
- No.of HBond Acceptors15
- No.of Rotatable Bonds13
- TPSA224.45
- StatusFDA approved
- AdministrationIV
- PharmacologyA clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein binding94.0
- Volume of distribution (VD)95~150 L/m2 (from various studies), also reported as 113 L.
- Blood/Plasma Partitioning ratio (D_blood)Little interaction with red blood cells.
- MetabollsmDocetaxel is rapidly distributed throughout the body into body tissue and is extensively metabolised by the hepatic cytochromes of the CYP3A group.
- Half life13.6 h
- ExcretionExcretion is mainly in faeces (75%) as one major and three minor inactive metabolites and a very low amount of the unchanged drug.
- Urinary Excretion2.1
- Clerance17~22 L/h/m2 (as reported in various literature).
- ToxicityThe maximum tolerated dose is 90 mg/m2 as a 24-h infusion. Development of severe peripheral neurotoxicity has been observed in 4.1% of patients.
- LD50 (rat)>2000 mg/kg
- LD50 (mouse)N/A